Medtronic Ardian Luxembourg S.a.r.l.

Medtronic Vascular, Inc.

Medtronic Ireland Manufacturing Unlimited Company

Sola International Holdings Limited

Paul John Coates

Douglas A Hettrick

Robert Melder

Martin Terry Rothman

Dustin Thompson

Larry Childs

Julie Trudel

Lance Ensign

Rui Lam

Jerry Warmerdam

Sean Salmon

Justin Eckhardt

Charlie Dawson

Michael Costa

Bob Boldig

Stefan Stoyanov Tunev

Michael Neidert

Stefan S Tunev

Helena Kloubek

Brian Cook

Matthew John Cuthbertson

Peter Wallace Coldrey

In some examples, a catheter includes an elongated member comprising an electrode array including a distal electrode, a proximal electrode proximal to the distal electrode, and at least one intermediate electrode between the proximal and distal electrodes. The at least one intermediate electrode and at least one of the distal electrode or the proximal electrode differ in at least one electrode characteristic by at least a predetermined threshold. In some examples, delivery of a given electrical signal by each of the at least one intermediate electrode and the at least one of the distal electrode or the proximal electrode generates, for a given tissue site, substantially similar electric fields. In other examples, delivery of a given electrical signal by each of the at least one intermediate electrode and the at least one of the distal electrode or the proximal electrode generates, for a given tissue site, different electric fields.

Multielectrode catheter

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a blood flow rate through the renal blood vessel via the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the blood flow rate through the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline and post-neuromodulation measurements are obtained by injecting an indicator fluid into the renal blood vessel upstream of the target site and detecting a transient change in vessel impedance caused by the indicator fluid.

Systems and methods for assessing efficacy of renal neuromodulation therapy

Systems and methods for determining modified fractional flow reserve values of vascular lesions are provided. Patient physiologic data, including coronary vascular information, is measured. According to the physiologic data, a coronary vascular model is generated. Lesions of interest within the coronary vascular system of the patient are identified for modified fractional flow reserve value determination. The coronary vascular model is modified to generate modified blood flow information for determining the modified fractional flow reserve value.

System and methods for determining modified fractional flow reserve values

Neuromodulation catheter systems with controlled irrigation capabilities and methods for using such systems are disclosed herein. One such method includes, for example, positioning an irrigated neuromodulation catheter at a treatment site within a renal blood vessel of a human patient, delivering neuromodulation energy at the treatment site, and delivering irrigation fluid to the treatment site having characteristics coordinated with the delivered energy. The characteristics can be adjusted to maintain an energy delivery element and/or tissue of the blood vessel at a constant temperature as power is increased. The method can further include monitoring at least one parameter of the tissue and/or of the energy delivery element, and adjusting the neuromodulation energy and/or the characteristics of the irrigation fluid if the at least one parameter falls outside of a treatment range of values.

Controlled irrigation for neuromodulation systems and associated methods

Example systems and techniques for denervation, for example, renal denervation. In some examples, a processor determines one or more tissue characteristics of tissue proximate a target nerve and a blood vessel. The processor may generate, based on the one or more tissue characteristics, an estimated volume of influence of denervation therapy delivered by a therapy delivery device disposed within the blood vessel. The processor may generate a graphical user interface including a graphical representation of the tissue proximate the target nerve and the blood vessel and a graphical representation of the estimated volume of influence.

Denervation therapy

Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, positioning a plurality of reference electrodes at the skin of a human patient and intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include obtaining impedance measurements between different combinations of the reference electrodes and the ablation electrodes and, based on the impedance measurements, identifying two or more electrode groups for treatment, where at least two of the electrode groups include a different one of the reference electrodes and a different one of the ablation electrodes.

Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting

Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include analyzing a renal neuromodulation target site of a patient to obtain patient-specific data related to the renal neuromodulation target site, and based on the patient specific data, delivering neuromodulation treatment to the patient via one or more of the ablation electrodes.

Systems, devices, and associated methods for neuromodulation in heterogeneous tissue environments

Devices and systems for the selective positioning of an intravascular neuromodulation device are disclosed herein. Such systems can include, for example, an elongated shaft and a therapeutic assembly carried by a distal portion of the elongated shaft. The therapeutic assembly is configured for delivery within a blood vessel. The therapeutic assembly can include a pre-formed shape and can be transformable between a substantially straight delivery configuration; and a treatment configuration having the pre-formed helical shape to position the therapeutic assembly in stable contact with a wall of the body vessel. The therapeutic assembly can also include a mechanical decoupler operably connected to the therapeutic assembly that is configured to absorb at least a portion of a force exerted on the therapeutic assembly by the shaft so that the therapeutic assembly maintains a generally stationary position relative to the target site.

Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems and methods

Devices and systems for the selective positioning of an intravascular neuromodulation device are disclosed herein. Such systems can include, for example, an elongated shaft and a therapeutic assembly carried by a distal portion of the elongated shaft. The therapeutic assembly is configured for delivery within a blood vessel. The therapeutic assembly can include one or more energy delivery elements configured to deliver therapeutic energy to nerves proximate a vessel wall.

Catheter apparatuses for modulation of nerves in communication with pulmonary system and associated systems and methods

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a dimension of the renal blood vessel via a sensing element of the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the dimension of the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline measurement is obtained via the sensing element of the neuromodulation catheter prior to delivering the neuromodulation energy.

Growing community of inventors

Corte Madera, CA, United States of America

Paul John Coates